FDA rejects Lilly bid to expand Erbitux-WEB ONLY
Indianapolis-based Elli Lilly and Co. and New York-based partner Bristol-Myers Squibb Co. have failed to win U.S. approval to sell Erbitux as a first-line treatment for head and neck cancers. Regulators questioned differences in American and European versions of the drug, which is already approved to treat colon tumors and certain drug-resistant head-and-neck malignancies. The […]